ES2723778T3 - Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos - Google Patents

Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos Download PDF

Info

Publication number
ES2723778T3
ES2723778T3 ES10816100T ES10816100T ES2723778T3 ES 2723778 T3 ES2723778 T3 ES 2723778T3 ES 10816100 T ES10816100 T ES 10816100T ES 10816100 T ES10816100 T ES 10816100T ES 2723778 T3 ES2723778 T3 ES 2723778T3
Authority
ES
Spain
Prior art keywords
cancer
stem cells
resistant
against drug
therapy directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10816100T
Other languages
English (en)
Inventor
Angelika Burger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMINOX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMINOX Inc filed Critical KOMINOX Inc
Application granted granted Critical
Publication of ES2723778T3 publication Critical patent/ES2723778T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un agente terapéutico para su uso en el tratamiento del cáncer de próstata resistente a paclitaxel o resistente a docetaxel que comprende (1) una composición que comprende meta arsenito de sodio y (2) una composición que comprende paclitaxel o docetaxel, respectivamente.
ES10816100T 2009-09-10 2010-09-09 Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos Active ES2723778T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10
PCT/US2010/048308 WO2011031890A2 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Publications (1)

Publication Number Publication Date
ES2723778T3 true ES2723778T3 (es) 2019-09-02

Family

ID=43647965

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10816100T Active ES2723778T3 (es) 2009-09-10 2010-09-09 Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos

Country Status (24)

Country Link
US (1) US20110059186A1 (es)
EP (1) EP2475362B1 (es)
JP (1) JP5710619B2 (es)
KR (2) KR101721009B1 (es)
CN (2) CN102753164A (es)
AR (1) AR079000A1 (es)
AU (1) AU2010292192B2 (es)
BR (1) BR112012008315B1 (es)
CA (1) CA2772411C (es)
CY (1) CY1121973T1 (es)
DK (1) DK2475362T3 (es)
ES (1) ES2723778T3 (es)
HU (1) HUE043387T2 (es)
IN (1) IN2012DN02008A (es)
LT (1) LT2475362T (es)
MX (1) MX2012002855A (es)
PL (1) PL2475362T3 (es)
PT (1) PT2475362T (es)
RU (1) RU2568834C2 (es)
SG (2) SG10201608967WA (es)
SI (1) SI2475362T1 (es)
TR (1) TR201905548T4 (es)
TW (1) TWI564012B (es)
WO (1) WO2011031890A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Ｈｒｐ-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
AU2018271937A1 (en) * 2017-05-24 2019-11-28 The Regents Of The University Of California Antisense therapies for treating cancer
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
CA2183547C (en) * 1994-02-18 2002-05-14 Tamara Vasilievna Vorobieva Compositions for treating defective cell functions
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
EP1374875A3 (en) * 1997-10-15 2004-01-07 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome
JP2001522799A (ja) * 1997-11-10 2001-11-20 メモリアル スローン−ケタリング キャンサー センター 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
DK1496918T3 (da) * 2002-04-10 2023-05-15 Komipharm Int Co Ltd Anvendelse af natriummetaarsenit til behandling af tumorer
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
KR20120048706A (ko) * 2009-09-18 2012-05-15 코미녹스 인코포레이티드 뇌종양 치료 방법

Also Published As

Publication number Publication date
WO2011031890A3 (en) 2011-08-25
JP2013504587A (ja) 2013-02-07
TWI564012B (zh) 2017-01-01
CY1121973T1 (el) 2020-10-14
EP2475362A4 (en) 2013-03-27
KR20150038702A (ko) 2015-04-08
EP2475362A2 (en) 2012-07-18
SG10201608967WA (en) 2016-12-29
PT2475362T (pt) 2019-05-27
LT2475362T (lt) 2019-06-10
WO2011031890A2 (en) 2011-03-17
US20110059186A1 (en) 2011-03-10
RU2568834C2 (ru) 2015-11-20
JP5710619B2 (ja) 2015-04-30
CA2772411A1 (en) 2011-03-17
HUE043387T2 (hu) 2019-08-28
MX2012002855A (es) 2012-07-20
DK2475362T3 (da) 2019-06-03
EP2475362B1 (en) 2019-03-27
WO2011031890A4 (en) 2011-10-13
AU2010292192B2 (en) 2015-04-02
SI2475362T1 (sl) 2019-08-30
RU2012108144A (ru) 2013-10-20
PL2475362T3 (pl) 2019-09-30
TW201114430A (en) 2011-05-01
TR201905548T4 (tr) 2019-05-21
CN102753164A (zh) 2012-10-24
KR20120061908A (ko) 2012-06-13
BR112012008315B1 (pt) 2021-08-03
AR079000A1 (es) 2011-12-21
BR112012008315A2 (pt) 2016-09-13
CA2772411C (en) 2017-08-22
KR101721009B1 (ko) 2017-03-29
SG179069A1 (en) 2012-04-27
AU2010292192A1 (en) 2012-03-29
CN107412771A (zh) 2017-12-01
IN2012DN02008A (es) 2015-07-24

Similar Documents

Publication Publication Date Title
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
IN2012DN02018A (es)
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CR20120528A (es) Métodos para tratar el cáncer
CR11723A (es) Agente para tratar enfermedad
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
NI201200179A (es) Métodos de tratamiento contra el cáncer pancreático
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
ES2530462T3 (es) Combinación terapia antitumoral
NI201200090A (es) Composiciones para tratar náusea y vómito centralmente mediados
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
BRPI0810384B8 (pt) terapia enzimática anticâncer
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
MX2019013862A (es) Terapia de combinacion.
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.